Daily Medication Pearl: Dalbavancin (Dalvance)

Author(s):

Saro Arakelians, PharmD

Dalbavancin (Dalvance) is indicated for acute bacterial skin and skin structure infections caused by designated susceptible strains of Gram-positive microorganisms.

Medication Pearl of the Day: Dalvance (dalbavancin)

Indication: Dalbavancin (Dalvance) is indicated for acute bacterial skin and skin structure infections (ABSSSI) caused by designated susceptible strains of Gram-positive microorganisms.

Insight:

Dosing: Two-dose regimen 1000 mg followed 1 week later by 500 mg.
Dosage forms: For injection 500 mg of lyophilized powder in a single-use vial for reconstitution.
Adverse events: The most common adverse reactions in patients treated with dalbavancin were nausea (5.5%), headache (4.7%), and diarrhea.
Mechanism of action: Dalbavancin, a semisynthetic lipoglycopeptide, interferes with cell wall synthesis by binding to the D-alanyl-D-alanine terminus of the stem pentapeptide in nascent cell wall peptidoglycan, thus preventing cross-linking.

Source: LABEL (fda.gov)